MOL CANCER 润色咨询

Molecular Cancer

出版年份：2002 年文章数：971 投稿命中率： 开通期刊会员，数据随心看

出版周期：Irregular 自引率：2.0% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2022-12-22 wooshiwo 来自辽宁省

    偏重的研究方向：肿瘤
    经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-10-26 ms4000001583479348 来自北京

    终于接收啦 历经四个月。希望杂志越来越好吧。

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-11-12 wym0577 来自浙江省

    审稿速度:3.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤
    经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-08-07 ms4000001583479348 来自北京

    审稿速度:2.0
    偏重的研究方向：circRNA;肿瘤
    经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀

    7

    展开7条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2022-01-21 summereason

    editor invited三个月，这杂志是怎么了？？？

    27

    展开27条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-10-20 ms1000001749825166 来自江苏省

    很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-10-09 summereason 来自江苏省

    审稿速度:12.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤;表观遗传
    经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-10-09 summereason 来自江苏省

    偏重的研究方向：circRNA;肿瘤;表观遗传
    经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-09-01 ms9508293866653270 来自陕西省

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤
    经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2107030, encodeId=9442210e03044, content=偏重的研究方向：肿瘤<br>经验分享：各位前辈，近期向molecular cancer 投了一篇综述，一审2个月后给了major revision，修回后二审1个月现在状态显示为“Reviewer reports received / Ready for editor’s decision”，已经3天了没有任何变化，一般这种状态多长时间会有结果？不会是因为快过圣诞节了，编辑都休假了导致延迟吧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a80877658, createdName=wooshiwo, createdTime=Thu Dec 22 09:54:37 CST 2022, time=2022-12-22, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2164991, encodeId=137d2164991bb, content=终于接收啦 历经四个月。希望杂志越来越好吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Thu Oct 26 10:02:22 CST 2023, time=2023-10-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2168164, encodeId=8986216816469, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：3个月大修，提了30多个问题，需要补充一些实验，目前还在补实验中，请问下大修的后续录用的概率是多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c7737624, createdName=wym0577, createdTime=Sun Nov 12 22:28:34 CST 2023, time=2023-11-12, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0<br>偏重的研究方向：circRNA;肿瘤<br>经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1186865, encodeId=0d181186865d7, content=editor invited三个月，这杂志是怎么了？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Fri Jan 21 16:20:23 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163852, encodeId=929f216385290, content=很难投中，绝不是传说中的可以拿来灌水的水平，没有扎实的工作量基本上秒拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0eb8776124, createdName=ms1000001749825166, createdTime=Fri Oct 20 00:25:46 CST 2023, time=2023-10-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161782, encodeId=e65d2161e8249, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:39:18 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2161783, encodeId=52962161e8316, content=偏重的研究方向：circRNA;肿瘤;表观遗传<br>经验分享：关注该期刊的Research系列文章一年了，为编辑部即使发现问题并调整方向感到高兴，目前稿源的研究方向、地区分布比例比之前有较大提升，每期也不乏大量漂亮的科研工作。诚然，依然有些工作看起来逊色于这个IF，总体来说还是稳中向好吧，希望杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5612360146, createdName=summereason, createdTime=Mon Oct 09 17:41:48 CST 2023, time=2023-10-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2155569, encodeId=9cde2155569d9, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：该杂志已经开始要原始数据了，客观的讲，Molecular Cancer目前的拒稿率现在还是很高的，说好中的，现在投一篇试试呢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Fri Sep 01 09:18:53 CST 2023, time=2023-09-01, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2157742, encodeId=d09f215e74211, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤;CAF<br>经验分享：有难度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=37612439660, createdName=123d1060m49(暂无昵称), createdTime=Thu Sep 14 21:35:57 CST 2023, time=2023-09-14, status=1, ipAttribution=重庆)]
    2023-09-14 123d1060m49(暂无昵称) 来自重庆

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤;CAF
    经验分享：有难度

    1

    展开1条回复
共500条页码: 2/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分